Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Chinese Academy of Sciences | 2 |
| 2 | Institute of Chinese Materia Medica of China Academy of Chinese Medical Sciences | 2 |
| 3 | Anhui Medical University | 1 |
| 4 | CapitalBio Corp | 1 |
| 5 | Excrx Singapore Pte Ltd | 1 |
| 6 | Lion Corp | 1 |
| 7 | State Grid Corp of China | 1 |
| 8 | University of Pennsylvania | 1 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 112 |
| 2 | A61P | Therapeutic activity (drug indications) | 53 |
| 3 | G01N | Investigating / analysing materials | 51 |
| 4 | Y02A | Climate change adaptation | 41 |
| 5 | A23L | Foods and beverages (general) | 25 |
| 6 | A61Q | Cosmetics, personal care | 20 |
| 7 | A23V | Foods, foodstuffs - indexing scheme | 14 |
| 8 | A01G | 10 | |
| 9 | A01N | Preservation of bodies; biocides; pest repellents | 10 |
| 10 | C07D | Heterocyclic compounds | 10 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Endophytic fungi capable of improving content of isofraxidin in Radix Acanthopanacis Semticosi through fermenting Radix Acanthopanacis Semticosi | 2012 | 6 | |
| Technology for synchronously extracting isofraxidin and flavonoids compounds from sarcandra glabra and applications thereof | 2010 | 5 | |
| One kind prepares isofraxidin method from Chinese medicinal material of sarcandra glaber | 2017 | 2 | |
| Method for extracting isofraxidin | 2011 | 2 | |
| Isofraxidin crystalline compound and glabrous sarcandra herb dispersible tablets and dropping pills containing isofraxidin crystalline compound | 2012 | 1 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 5 |
| 2017 | 3 |
| 2018 | 4 |
| 2019 | 2 |
| 2020 | 4 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 4 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Kaishun Bi | Shenyang Pharmaceutical University | 6 |
| 2 | Xijun Wang | Heilongjiang University of Chinese Medicine | 5 |
| 3 | Haitao Lv | Heilongjiang University of Chinese Medicine | 5 |
| 4 | Taisuke Yamazaki | Kohno Clinical Medicine Research Institute | 4 |
| 5 | Weifeng Li | Xi'an Jiaotong University | 4 |
| 6 | Yanmei Zhang | Heilongjiang University of Chinese Medicine | 4 |
| 7 | Hongxin Cao | China Academy of Chinese Medical Sciences | 4 |
| 8 | Zhide Hu | Lanzhou University | 3 |
| 9 | Hui Sun | Shenyang Pharmaceutical University | 3 |
| 10 | Xiaofeng Niu | Xi'an Jiaotong University | 3 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Constituents and pharmacological effects of Eucommia and Siberian ginseng. | 2001 | 261 | Natural product bioactivities and synthesis |
| Interaction of isofraxidin with human serum albumin | 2003 | 128 | Drug Transport and Resistance Mechanisms |
| Isofraxidin exhibited anti-inflammatory effects in vivo and inhibited TNF-α production in LPS-induced mouse peritoneal macrophages in vitro via the MAPK pathway | 2012 | 92 | Genomics, phytochemicals, and oxidative stress |
| Isofraxidin, a Coumarin Component from Acanthopanax senticosus, Inhibits Matrix Metalloproteinase-7 Expression and Cell Invasion of Human Hepatoma Cells | 2010 | 86 | Natural product bioactivities and synthesis |
| Isofraxidin, a potent reactive oxygen species (ROS) scavenger, protects human leukemia cells from radiation-induced apoptosis via ROS/mitochondria pathway in p53-independent manner | 2014 | 80 | Genomics, phytochemicals, and oxidative stress |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular structure and chemical formula of Isofraxidin?
Which organizations hold patents for Isofraxidin applications?
What are the main research topics associated with Isofraxidin in published literature?
Who are the most prolific authors publishing research on Isofraxidin?
What is the current patent activity trend for Isofraxidin?